乌鸦传媒

Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined 乌鸦传媒 in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining 乌鸦传媒, he was managing editor of Cancer Network, directing the website鈥檚 news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

ASCO over a computer rendering of a cancer cell and lymphocytes

<乌鸦传媒>Small PFS Bump in Synovial Sarcoma With Novel Drug

But questions raised over control arm and whether improvement represents a meaningful benefit

ASCO over a computer rendering of a cancer cell and lymphocytes

<乌鸦传媒>Radioligand Therapy Boosts Survival in Metastatic CRPC

PSMA-directed agent improved overall survival by median 4 months

ASCO over a computer rendering of a cancer cell and lymphocytes

<乌鸦传媒>'A Quantum Leap Forward': Potential New Standard in High-Risk RCC

Adjuvant immunotherapy led to 32% reduction in the risk of recurrence, positive trend in OS

COVID-19 UPDATE and Other News over a background of illustrated coronaviruses

<乌鸦传媒>Guns for Vaccinations; IU Health Joins the Mandate Club; NFL Ends 'Race-Norming'

A daily roundup of news on COVID-19 and the rest of medicine

FDA ODAC pembrolizumab (Keytruda), nivolumab (Opdivo) over a micrograph of hepatocellular carcinoma

<乌鸦传媒>FDA Panel Splits on Anti-PD-1 Monotherapy in HCC

All thumbs up for pembrolizumab, pending further data, but no such luck for nivolumab

AACR over a computer rendering of a tumor

<乌鸦传媒>Targeted Drug Yields Durable Responses in Rare Blood Neoplasm

Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor

AACR over a computer rendering of a tumor

<乌鸦传媒>Dual Targeted Tx a 'Meaningful' Option in BRAF-Mutant Glioma

One-third of glioblastoma patients responded to dabrafenib-trametinib

AACR over a computer rendering of a tumor

<乌鸦传媒>Immunovirotherapy Shows Promise in Pediatric High-Grade Glioma

Small study showed responses in 11 of 12 patients

AACR over a computer rendering of a tumor

<乌鸦传媒>Nivolumab Alone Prevails in Resected Melanoma

Adding ipilimumab in adjuvant setting failed to improve relapse-free survival

AACR over a computer rendering of a tumor

<乌鸦传媒>Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL

Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity

鈥�

20

鈥�